Mirati Therapeutics To Present At Upcoming Healthcare Conferences

Rhea-AI Summary

Mirati Therapeutics (NASDAQ: MRTX), a late-stage oncology firm, will present at two key healthcare conferences in late February and early March 2021. The first presentation is on February 26 at the 10th Annual SVB Leerink Global Healthcare Conference, featuring Dan Faga in a fireside chat. The second is on March 3 at the 41st Annual Cowen Healthcare Conference, with Charles M. Baum leading the discussion. Both presentations will be available via webcast on the company's website for 90 days after the events.

SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.

• Friday, February 26^th at 12:00 p.m. EST/9:00 a.m. PST at the 10^th Annual SVB Leerink Global Healthcare Conference. Dan Faga, executive vice president and chief operating officer will represent Mirati in a fireside chat at the conference.
• Wednesday, March 3^rd at 2:00 p.m. EST/11:00 a.m. PST at the 41^st Annual Cowen Healthcare Conference. Charles M. Baum, M.D., Ph.D., president and chief executive officer will represent Mirati in a fireside chat at the conference.

The webcast will be available through the "Investors" section of the Mirati website, Mirati Investor Events and Presentations, and a replay of the webcast will be made available for 90 days following the event.

About Mirati Therapeutics 

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of cancer patients and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.  Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies.  Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer. 

For more information about Mirati Therapeutics, visit us at Mirati.com or follow us on LinkedIn.   

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-at-upcoming-healthcare-conferences-301231242.html

SOURCE Mirati Therapeutics, Inc.

FAQ

When is Mirati Therapeutics presenting at the healthcare conferences in 2021?

Mirati Therapeutics will present on February 26 at the SVB Leerink Global Healthcare Conference and on March 3 at the Cowen Healthcare Conference.

Who will represent Mirati Therapeutics at the SVB Leerink Global Healthcare Conference?

Dan Faga, executive vice president and chief operating officer, will represent Mirati Therapeutics.

What is the ticker symbol for Mirati Therapeutics?

The ticker symbol for Mirati Therapeutics is MRTX.

How can I access the webcast of Mirati's conference presentations?

The webcasts of Mirati's presentations will be available on their website under the 'Investors' section for 90 days after the events.

What is the focus of Mirati Therapeutics' research?

Mirati Therapeutics focuses on developing therapies for cancer, particularly targeting genetic and immunological drivers.